Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track VKTX with free AI briefings, catalyst countdowns, and dilution alerts.

VKTX · Viking Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$165.8M Cash on Hand

7.6mo Cash Runway

25.1% Short Interest

$92.72 Analyst Target (18)

Follow VKTX by email Get an email when VKTX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about VKTX, unsubscribe in one click. Privacy

📣 What VKTX Says Is Next

fourth quarter of this year · VK2735: “During the second quarter, the company continued to prepare for initiation of these studies, which are expected to begin in the fourth quarter of this year.”
Company press release, Jul 29, 2026 · SEC filing
this year · “Our VANQUISH Phase 3 studies of the subcutaneous formulation are fully enrolled, and our planned Phase 3 studies with the oral tablet formulation are expected to begin later this year, marking a rapid pace of development for this important program.”
Company press release, Apr 29, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

🧪 Trial & FDA Catalysts

Jul 2027 · Phase 3 · Recruiting · VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
Registry primary completion date, not a results date
Jul 2027 · Phase 3 · Active Trial · VK2735 for Weight Management Phase 3
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
VK2735	Weight Loss	Phase 3 · NCT07104500	Active not recruiting
VK2809	NASH - Nonalcoholic Steatohepatitis	Phase 2 · NCT04173065	Completed
VK5211	Hip Fractures	Phase 2 · NCT02578095	Completed
VK0214	Adrenomyeloneuropathy Form (AMN) of X-linked Adren	Phase 1 · NCT04973657	Completed
VK2735 Drug	Obese Adults	Phase 1 · NCT07838740	Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

VKTX holds $165.8M in cash and short-term investments and burns about $65.4M/quarter from operations, an estimated runway of 7.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 33 · Moderate

Cash runway 12 months +18
ATM program on file since Jul 2026 +15
Shelf registration (S-3ASR, Jul 2026) +10
Raised after last reported balance sheet (Sep 2026) -10

Recent financing filings on SEC EDGAR:

Sep 25, 2026 · Convertible notes offering, $275M · 424B5
Sep 25, 2026 · Convertible notes offering · 424B5
Sep 23, 2026 · Convertible notes offering · 424B5
Sep 23, 2026 · Convertible notes offering · 424B5
Jul 30, 2026 · Shelf registration with ATM program, up to $500M · S-3ASR
Mar 1, 2024 · ATM program, up to $152M · 424B5

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VKTX files for a raise →

👥 Who Owns VKTX

Insiders Form 4 data not loaded yet Institutions (571 holders) 60.6% Public and other holders 39.4%

Holder	Type	Shares	% of shares	As of
Vanguard Group Inc	Institution (13F)	9,984,487	8.56%	2025-12-31
Blackrock Inc.	Institution (13F)	6,611,874	5.67%	2025-12-31
FMR, LLC	Institution (13F)	6,557,766	5.62%	2025-12-31
State Street Corporation	Institution (13F)	4,445,430	3.81%	2025-12-31
Morgan Stanley	Institution (13F)	3,076,270	2.64%	2025-12-31
Two Sigma Investments, LP	Institution (13F)	2,435,737	2.09%	2025-12-31
Two Sigma Advisers, LP	Institution (13F)	2,129,228	1.83%	2025-12-31
Geode Capital Management, LLC	Institution (13F)	1,994,509	1.71%	2025-12-31
Citadel Advisors Llc	Institution (13F)	1,732,421	1.49%	2025-12-31
Shaw D.E. & Co., Inc.	Institution (13F)	1,718,493	1.47%	2025-12-31

Share count 116,652,937 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2025-12-31). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade date	Insider	Transaction	Shares	Price	Owned after
2026-08-01 filed 2026-08-07	Kelly-Gemmell Dorothy Elizab	Award (A)	6,333	–	6,333
2026-08-01 filed 2026-08-07	Kelly-Gemmell Dorothy Elizab	Option award (A)	40,800	–	–
2026-07-29 filed 2026-07-29	Lian Brian	Sale (S)	148,517	$33.32	2,572,441
2026-07-29 filed 2026-07-29	Mancini Marianna	Sale (S)	18,217	$33.47	422,760
2026-07-29 filed 2026-07-29	ZANTE GREG	Sale (S)	21,217	$33.47	212,204

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full VKTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VKTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z